In breast cancer, particularly in triple-negative breast cancer (TNBC), FOXM1 contributes significantly to treatment resistance by regulating DNA repair genes and protecting cancer cells from DNA damage, while the presence of both high FOXM1 and KPNA2 expression correlates with poorer clinical outcomes and increased resistance to various therapies, including endocrine treatments and chemotherapy [16,17,18,19]. Here, FOXM1 is linked to breast carcinoma.